Among women ≤50 years, both cancer cohorts consistently showed higher frequencies of BIM deletion polymorphism than healthy volunteers (consecutive cancer cohort, 23% vs.13%, P = 0.005; metastatic cancer cohort, 25% vs. 13%, P = 0.010). Here, BCL2L11 is linked to cancer.